key: cord-0826940-5kari28a authors: Liu, Wang-Da; Hung, Chien-Ching; Wang, Jann-Tay; Tsai, Ming-Jui; Kuo, Po-Hsien; Chao, Tai-Ling; Hsieh, Szu-Min; Sheng, Wang-Huei; Chen, Yee-Chun; Chang, Sui-Yuan; Chang, Shan-Chwen title: Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19 date: 2021-04-21 journal: J Formos Med Assoc DOI: 10.1016/j.jfma.2021.04.010 sha: 173dc228f5f2c2b9116026d3bea2136f08cdf73d doc_id: 826940 cord_uid: 5kari28a We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms. concurrently have COVID-19 is less clear. 2 Several reports suggested that PLWH might 23 be at an increased risk of severe COVID-19 disease, especially among those with 24 lower CD4 cell counts or unsuppressed HIV viral replication. 3 However, for those who 25 are receiving antiretroviral therapy (ART) with sustained viral suppression and 26 recovery of CD4 count, the clinical course and immune response to COVID-19 might 27 be modified. 4 Here we present the clinical course and antibody response of an 28 individual with HIV infection who was affected by COVID-19. 29 30 Case Report 31 The 38-year-old man had developed watery diarrhea four days prior to this 32 and dry cough ensued. He was admitted to a negative-pressure isolation room at the 34 National Taiwan University Hospital upon his return to Taiwan with deteriorating 35 symptoms. SARS-CoV-2 was later identified by real-time reverse 36 transcription-polymerase chain reaction (RT-PCR) assay of a throat swab specimen. The results of plaque reduction neutralizing assay are shown in Figure 2 and 100 Table 1 . Neutralizing effect was not significantly observed from the serum sampled 101 on the ninth day after the symptom onset, while the serum specimens collected on 102 the 26 th and 47 th day continued to have a considerable neutralizing effect. However, 103 such neutralizing effect gradually diminished over time, from 61% to 36% of the 104 serum specimens collected from 47 th to 158 th day, with an 80-fold dilution, 105 respectively. Compared with the neutralizing effect of the serum collected from this 106 patient against SARS-CoV-2 with (NTU03) or without (NTU04) D614G mutation, we 107 found that the neutralizing effect was detected earlier against the virus without 108 SARS-CoV-2 with or without D614G mutation was still observed. Previous studies also highlighted that the disease severity could be associated 143 with neutralizing antibody responses. 10 Factors associated with COVID-19-related death using OpenSAFELY COVID-19 in patients with HIV: clinical case series Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV Prolonged virus shedding even after seroconversion in a patient with COVID-19 Virological assessment of hospitalized patients with COVID-2019 Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19 Clinical characteristics, comorbidities and outcomes among persons with HIV hospitalized with coronavirus disease Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients High neutralizing antibody titer in intensive care unit patients with COVID-19